X-ray psoralen activated cancer therapy (X-PACT)

Patent metadata

Field	Value
Publication number	US-10441810-B2
Application number	US-201715434871-A
Country	US
Kind code	B2
Filing date	Feb 16, 2017
Priority date	Apr 8, 2007
Publication date	Oct 15, 2019
Grant date	Oct 15, 2019

Abstract

A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

First claim

The invention claimed is:

1. A method for treating a diseased site in a human or animal body, comprising:
injecting in a diseased site a pharmaceutical carrier including one or more phosphors which are capable of emitting light in the human or animal body;
infusing the diseased site with a photoactivatable drug;
applying x-ray or high energy electrons to the diseased site;
producing from the phosphors said light inside the diseased site and thereby photoactivating the photoactivatable drug;
from the photoactivated drug, producing a cytotoxicity inside the diseased site of greater than 20%;
providing a booster treatment to the diseased site, before, during and/or after an initial treatment of the diseased site, and
delaying a period between booster treatments according to a tolerance level of the human or animal body for radiation-modified cells generated during the booster treatment.

2. The method of claim 1 , wherein applying x-ray or high energy electrons comprises providing a controlled radiation dose to the diseased site.

3. The method of claim 1 , wherein said booster treatment is performed before an initial treatment of the diseased site.

4. The method of claim 1 , wherein said booster treatment is performed during an initial treatment of the diseased site.

5. The method of claim 1 , wherein said booster treatment is performed after an initial treatment of the diseased site.

6. The method of claim 5 , wherein said booster treatment is repeated on a periodic basis after an initial treatment of the diseased site.

7. The method of claim 1 , wherein, in the booster treatment, at least one of phosphor concentration, photoactivatable drug concentration, and the radiation dose is increased by a factor of at least two times respective initial values.

8. The method of claim 1 , wherein the booster treatment produces psoralen-modified cancer cells or X-ray modified cancer cells.

9. The method of claim 1 , wherein the booster treatment produces radiation damaged cancer cells.

10. The method of claim 1 , wherein the booster treatment provides radiating the human or animal body at either a palliative or therapeutic level.

11. The method of claim 10 , wherein the radiating the human or animal body at either a palliative or therapeutic level comprises radiating the diseased site before, during, and/or after an initial treatment with said phosphors, said photoactivatable drug, and said applying x-ray or high energy electrons to the diseased site.

12. The method of claim 1 , wherein applying x-ray or high energy electrons comprises providing a controlled radiation dose to a tumor.

13. The method of claim 12 , wherein applying x-ray or high energy electrons comprises providing a booster treatment to the tumor, said booster treatment repeated on a periodic basis after an initial treatment of the tumor.

14. The method of claim 1 , further comprising radiating the human or animal body at at least one of a palliative level, a therapeutic level, or a radiation induced cell kill level.

15. The method of claim 14 , wherein said radiating the human or animal body comprises radiating at said palliative level.

16. The method of claim 14 , wherein said radiating the human or animal body comprises radiating at said radiation induced cell kill level.

17. The method of claim 14 , wherein said radiating the human or animal body comprises radiating at said palliative level as an intervening treatment after an initial treatment with said phosphors, said photoactivatable drug, and said applying x-ray or high energy electrons to the diseased site and prior to a subsequent booster treatment with said phosphors, said photoactivatable drug, and said applying x-ray or high energy electrons to the diseased site.

18. The method of claim 1 , wherein the method further comprises, before, during, and/or after an initial treatment with said phosphors, said photoactivatable drug, and said applying x-ray or high energy electrons to the diseased site, radiating the human or animal body at a region different from the diseased site.

19. The method of claim 1 , wherein the method further comprises, before, during, and/or after an initial treatment with said phosphors, said photoactivatable drug, and said applying x-ray or high energy electrons to the diseased site, radiating the human or animal body at a region different from the diseased site with a palliative level of radiation.

20. The method of claim 1 , wherein the method further comprises, before, during and/or after an initial treatment with said phosphors, said photoactivatable drug, and said applying x-ray or high energy electrons to the diseased site, radiating the human or animal body at a region different from the diseased site with a radiation induced cell kill level of radiation.

21. The method of claim 1 , wherein said activating the photoactivatable drug causes an auto-vaccine effect in the human or animal body.

22. The method of claim 21 , further comprising stunting growth of a tumor in the human or animal body until the activated photoactivatable drug causes said auto-vaccine effect in the human or animal body.

23. The method of claim 21 , further comprising stimulating said auto-vaccine effect in the human or animal body.

24. The method of claim 23 , wherein stimulating said auto-vaccine effect comprises injecting a vaccine into the human or animal body.

25. The method of claim 24 , wherein stimulating said auto-vaccine effect comprises injecting a tetanus vaccine into the human or animal body.

26. The method of claim 23 , wherein stimulating said auto-vaccine effect comprises radiating the human or animal body with a palliative level of radiation.

27. A method for treating a diseased site in a human or animal body, comprising:
injecting in a diseased site a pharmaceutical carrier including one or more phosphors which are capable of emitting light in the human or animal body;
infusing the diseased site with a photoactivatable drug;
applying x-ray or high energy electrons to the diseased site;
producing from the phosphors said light inside the diseased site and thereby photoactivating the photoactivatable drug; and
from the photoactivated drug, producing a cytotoxicity inside the diseased site of greater than 20%;
radiating the human or animal body at a palliative level as an intervening treatment after an initial treatment with said phosphors, said photoactivatable drug, and said applying x-ray or high energy electrons to the diseased site and prior to a subsequent booster treatment with said phosphors, said photoactivatable drug, and said applying x-ray or high energy electrons to the diseased site.

28. The method of claim 27 , wherein applying x-ray or high energy electrons comprises providing a controlled radiation dose to the diseased site.

29. The method of claim 27 , wherein said booster treatment is repeated on a periodic basis after an initial treatment of the diseased site.

30. The method of claim 27 , wherein, in the booster treatment, at least one of phosphor concentration, photoactivatable drug concentration, and the radiation dose is increased by a factor of at least two times respective initial values.

31. The method of claim 27 , wherein the booster treatment produces psoralen-modified cancer cells or X-ray modified cancer cells.

32

Assignees

• Immunolight Llc
• Univ Duke

Inventors

• Oldham Mark
• Fathi Zakaryae
• Beyer Wayne F
• Walder Harold
• Bourke Jr Frederic A
• Dewhirst Mark
• Spector Neil L
• Yoon Paul
• Adamson Justus
• Alcorta David
• Lyerly Kim
• Liu Leihua
• Osada Takuya

Classifications

• A61N2005/1089

  Electrons · CPC title

• A61N5/062 Primary

  Photodynamic therapy, i.e. excitation of an agent · CPC title

• A61N2005/1098

  Enhancing the effect of the particle by an injected agent or implanted device · CPC title

• A61K35/00

  Medicinal preparations containing materials or reaction products thereof with undetermined constitution · CPC title

• A61N5/10

  X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) · CPC title